Literature DB >> 21956669

Endogenous nitric oxide formation correlates negatively with circulating matrix metalloproteinase (MMP)-2 and MMP-9 levels in black subjects.

Ingrid F Metzger1, Valéria C Sandrim, Jose E Tanus-Santos.   

Abstract

Deficient formation of endogenous nitric oxide (NO) contributes to cardiovascular diseases, and this may be associated with increased circulating levels of matrix metalloproteinase-9 (MMP-9), as previously shown in white subjects. Because interethnic differences exist with respect to risk factors, prevalence, and severity of cardiovascular diseases, we designed this study to examine whether the circulating levels of nitrites (a marker of endogenous NO formation) are associated with the plasma levels of MMP-9 and MMP-2 in healthy black subjects. We studied 198 healthy subjects self-reported as blacks not taking any medications. Venous blood samples were collected and plasma and whole blood nitrite levels were measured using an ozone-based chemiluminescence assay. Plasma MMP-2 and MMP-9 levels were determined by gelatin zymography. We found a positive correlation between plasma MMP-9 and MMP-2 levels (P < 0.0001, rs = 0.556). Interestingly, we found a negative relationship between the plasma MMP-9 levels and the plasma or whole blood nitrites levels (P = 0.04, rs = -0.149; and P < 0.0001, rs = -0.349, respectively). In parallel, we found similar negative relationships between plasma MMP-2 levels and plasma or whole blood nitrites levels (P = 0.02, rs = -0.172; and P < 0.0001, rs = -0.454, respectively). This is the first study to show that endogenous nitric oxide formation correlates negatively with the circulating levels of both MMP-2 and MMP-9 in black subjects. Our findings suggest a mechanistic link between deficient NO formation and increased MMPs levels, which may promote cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21956669     DOI: 10.1007/s11010-011-1079-8

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  51 in total

1.  Consistent interethnic differences in the distribution of clinically relevant endothelial nitric oxide synthase genetic polymorphisms.

Authors:  Aline S Marroni; Ingrid F Metzger; Debora C Souza-Costa; Sabrina Nagassaki; Valeria C Sandrim; Ronan X Correa; Fabricio Rios-Santos; Jose E Tanus-Santos
Journal:  Nitric Oxide       Date:  2005-05       Impact factor: 4.427

2.  Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans.

Authors:  Petra Kleinbongard; André Dejam; Thomas Lauer; Thomas Jax; Stefan Kerber; Putrika Gharini; Jan Balzer; Rainer B Zotz; Rüdiger E Scharf; Reinhart Willers; Alan N Schechter; Martin Feelisch; Malte Kelm
Journal:  Free Radic Biol Med       Date:  2005-11-10       Impact factor: 7.376

3.  Matrix metalloproteinase 9 gene haplotypes affect left ventricular hypertrophy in hypertensive patients.

Authors:  Riccardo Lacchini; Anna L B Jacob-Ferreira; Marcelo R Luizon; Fernanda B Coeli; Tatiane C Izidoro-Toledo; Sandra Gasparini; Maria C Ferreira-Sae; Roberto Schreiber; Wilson Nadruz; Jose E Tanus-Santos
Journal:  Clin Chim Acta       Date:  2010-08-11       Impact factor: 3.786

4.  Mechanism of inhibition of matrix metalloproteinase-9 induction by NO in vascular smooth muscle cells.

Authors:  M V Gurjar; J DeLeon; R V Sharma; R C Bhalla
Journal:  J Appl Physiol (1985)       Date:  2001-09

5.  Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological target.

Authors:  Vanessa Fontana; Pamela S Silva; Vanessa A Belo; Raquel C Antonio; Carla S Ceron; Celso Biagi; Raquel F Gerlach; Jose E Tanus-Santos
Journal:  Basic Clin Pharmacol Toxicol       Date:  2011-04-04       Impact factor: 4.080

6.  Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma.

Authors:  Raquel F Gerlach; Caroline Demacq; Klaus Jung; Jose E Tanus-Santos
Journal:  Clin Biochem       Date:  2006-10-19       Impact factor: 3.281

7.  Nitric oxide inhibition increases aortic wall matrix metalloproteinase-9 expression.

Authors:  Matthew J Eagleton; David A Peterson; Vita V Sullivan; Karen J Roelofs; John A Ford; James C Stanley; Gilbert R Upchurch
Journal:  J Surg Res       Date:  2002-05-01       Impact factor: 2.192

8.  Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis.

Authors:  Hossein Bahrami; Richard Kronmal; David A Bluemke; Jean Olson; Steven Shea; Kiang Liu; Gregory L Burke; João A C Lima
Journal:  Arch Intern Med       Date:  2008-10-27

9.  Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage.

Authors:  Andrew Webb; Richard Bond; Peter McLean; Rakesh Uppal; Nigel Benjamin; Amrita Ahluwalia
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-03       Impact factor: 11.205

10.  Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases.

Authors:  Leszek Kalinowski; Iwona T Dobrucki; Tadeusz Malinski
Journal:  Circulation       Date:  2004-05-24       Impact factor: 29.690

View more
  6 in total

1.  Inducible nitric oxide synthase haplotype associated with migraine and aura.

Authors:  Thiago de O S Mansur; Flavia M Gonçalves; Alisson Martins-Oliveira; Jose G Speciali; Fabiola Dach; Riccardo Lacchini; Jose E Tanus-Santos
Journal:  Mol Cell Biochem       Date:  2012-01-11       Impact factor: 3.396

2.  Nitric oxide attenuates matrix metalloproteinase-9 production by endothelial cells independent of cGMP- or NFκB-mediated mechanisms.

Authors:  Cesar A Meschiari; Tatiane Izidoro-Toledo; Raquel F Gerlach; Jose E Tanus-Santos
Journal:  Mol Cell Biochem       Date:  2013-03-03       Impact factor: 3.396

3.  Sodium nitrite attenuates MMP-9 production by endothelial cells and may explain similar effects of atorvastatin.

Authors:  Cesar A Meschiari; Lucas C Pinheiro; Danielle A Guimaraes; Raquel F Gerlach; Jose E Tanus-Santos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-11-28       Impact factor: 3.000

4.  Reductions of Circulating Nitric Oxide are Followed by Hypertension during Pregnancy and Increased Activity of Matrix Metalloproteinases-2 and -9 in Rats.

Authors:  Regina A Nascimento; Jose S Possomato-Vieira; Giselle F Bonacio; Elen Rizzi; Carlos A Dias-Junior
Journal:  Cells       Date:  2019-11-07       Impact factor: 6.600

Review 5.  Matrix Metalloproteinases and Arterial Hypertension: Role of Oxidative Stress and Nitric Oxide in Vascular Functional and Structural Alterations.

Authors:  Alejandro F Prado; Rose I M Batista; Jose E Tanus-Santos; Raquel F Gerlach
Journal:  Biomolecules       Date:  2021-04-16

Review 6.  Recent advances in enzyme-related biomaterials for arthritis treatment.

Authors:  Xin-Hao Liu; Jia-Ying Ding; Zhi-Heng Zhu; Xi-Chen Wu; Yong-Jia Song; Xiao-Ling Xu; Dao-Fang Ding
Journal:  Front Chem       Date:  2022-08-16       Impact factor: 5.545

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.